Concert Pharmaceuticals focuses on developing small molecule drugs to treat autoimmune diseases. The company's main product under development is CTP-543, which is currently being evaluated in a Phase III clinical trial as a treatment for alopecia areata. Concert Pharmaceuticals has partnerships with several other pharmaceutical companies to further its research and development efforts.